Compare iShares Core High Dividend ETF (HDV) vs Eli Lilly And Co (LLY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
iShares Core High Dividend ETF vs Eli Lilly And Co — how do they compare? iShares Core High Dividend ETF trades at $28.71 (market cap $14.68B), while Eli Lilly And Co trades at $1,179.27 (market cap $1.04T). The key difference: Eli Lilly And Co is far larger — about 70.8× iShares Core High Dividend ETF's market cap, and Eli Lilly And Co pays a 0.59% dividend while iShares Core High Dividend ETF pays none. Which is the better fit depends on your goals — on Pluang, investors hold iShares Core High Dividend ETF for 117 Days and Eli Lilly And Co for 93 Days on average.
| HDV | LLY | |
|---|---|---|
Market Cap | $14.68B | $1.04T |
Volume | 2,925,562 | 3,064,878 |
52-Week High | $29.93 | $1.28K |
52-Week Low | $23.64 | $799.57 |
Typical Hold Time | 117 Days | 93 Days |
Sector | — | Health |
Enterprise Value | — | $1.09T |
Dividend Yield | — | 0.59% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
HDV (iShares Core High Dividend ETF) trades at $28.82, up 1.91% with strong bullish technical signals from moving averages and oscillators. The ETF recently underwent a significant sector rebalancing, reducing healthcare exposure while increasing energy, staples, and utilities. Current dividend yield is approximately 3% with recent quarterly payouts between $0.06-$0.10 per share. Technical indicators show RSI at 77.74 suggesting potential overbought conditions near-term.
The outlook remains positive given the ETF's sector rotation toward defensive holdings and income focus, though concentration risk has increased with 62% in three sectors. Key risks include interest rate sensitivity and sector concentration, while opportunities lie in defensive positioning during market volatility. The 3% yield provides income appeal but requires monitoring of sector allocations.
Eli Lilly (LLY) trades at $1,169.93, down 1.58% on the day, but maintains strong bullish momentum with consistent earnings beats and robust revenue growth. The company demonstrates exceptional profitability with 83.4% gross margins and 33.53% net income margins, supported by dominant positioning in weight-loss and diabetes treatments. Recent clinical trial successes for next-generation drugs and expanded FDA approvals reinforce growth prospects.
LLY presents compelling growth potential with analyst consensus target of $1,350 representing 15% upside, though elevated valuations (P/E 39.26) and increasing competition in obesity drugs pose risks. Strong institutional support (73% buy ratings) and positive pipeline developments support continued momentum, but investors should monitor execution risks and market saturation concerns.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About iShares Core High Dividend ETF
The fund generally will invest at least 80% of its assets in the component securities of its underlying index and in investments that have economic characteristics that are substantially identical to the component securities of its underlying index. The underlying index is comprised of qualified income paying securities that are screened for superior company quality and financial health as determined by Morningstar, Inc.'s proprietary index methodology. The fund is non-diversified.
Read more on HDV →About Eli Lilly And Co
Eli Lilly is a drug firm with a focus on neuroscience, endocrinology, cancer, and immunology. Lilly's key products include Verzenio for cancer
Read more on LLY →
